124 related articles for article (PubMed ID: 2757962)
1. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy.
Campos L; Guyotat D; Archimbaud E; Devaux Y; Treille D; Larese A; Maupas J; Gentilhomme O; Ehrsam A; Fiere D
Br J Haematol; 1989 Jun; 72(2):161-6. PubMed ID: 2757962
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
[TBL] [Abstract][Full Text] [Related]
3. Surface marker expression in acute myeloid leukaemia at first relapse.
Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D
Br J Haematol; 1992 May; 81(1):40-4. PubMed ID: 1381608
[TBL] [Abstract][Full Text] [Related]
4. Role of blast cell immunophenotyping for the diagnosis and prognosis of acute myeloid leukemia.
Dubosc-Marchenay N; Lacombe F; Dumain P; Marit G; Montastruc M; Belloc F; Reiffers J
Hematol Oncol; 1992; 10(5):235-49. PubMed ID: 1493908
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies in myeloid diseases: prognostic use in acute myeloid leukaemia.
Kristensen JS; Hokland P
Leuk Res; 1991; 15(8):693-700. PubMed ID: 1895750
[TBL] [Abstract][Full Text] [Related]
6. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group.
Bradstock K; Matthews J; Benson E; Page F; Bishop J
Blood; 1994 Aug; 84(4):1220-5. PubMed ID: 8049437
[TBL] [Abstract][Full Text] [Related]
8. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
Mesárosová A; Hrivnáková A; Babusíková O
Neoplasma; 1993; 40(6):341-5. PubMed ID: 8289964
[TBL] [Abstract][Full Text] [Related]
10. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
11. Characterization of CD13 and CD33 surface antigen-negative acute myeloid leukemia.
Kraguljac N; Marisavljevic D; Jankovic G; Radosevic N; Pantic M; Donfrid M; Miletic N; Boskovic D; Colovic M
Am J Clin Pathol; 2000 Jul; 114(1):29-34. PubMed ID: 10884796
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
13. The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia.
Urbano-Ispizua A; Matutes E; Villamor N; Sierra J; Pujades A; Reverter JC; Feliu E; Cervantes F; Vives-Corrons JL; Montserrat E
Br J Haematol; 1992 Jun; 81(2):178-83. PubMed ID: 1322689
[TBL] [Abstract][Full Text] [Related]
14. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL).
Solary E; Casasnovas RO; Campos L; Béné MC; Faure G; Maingon P; Falkenrodt A; Lenormand B; Genetet N
Leukemia; 1992 May; 6(5):393-9. PubMed ID: 1375696
[TBL] [Abstract][Full Text] [Related]
15. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
[TBL] [Abstract][Full Text] [Related]
16. Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows.
Venditti A; Del Poeta G; Stasi R; De Fabriitis P; Coppetelli U; Bruno A; Simone MD; Papa G
Haematologica; 1993; 78(6):359-63. PubMed ID: 7513673
[TBL] [Abstract][Full Text] [Related]
17. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
19. CD7 expression in acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Cox C; Aronica G; Masi M; Bruno A; Simone MD; Buccisano F; Papa G
Leuk Lymphoma; 1995 Mar; 17(1-2):111-9. PubMed ID: 7539657
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML.
Marosi C; Köller U; Koller-Weber E; Schwarzinger I; Schneider B; Jäger U; Vahls P; Nowotny H; Pirc-Danoewinata H; Steger G
Cancer Genet Cytogenet; 1992 Jul; 61(1):14-25. PubMed ID: 1638477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
